Filtered By:
Source: Current Pharmaceutical Design

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 176 results found since Jan 2013.

Statins in stroke prevention: present and future.
CONCLUSION: Traditionally, there has been no clear data demonstrating that adding other lipid-modifying drugs to statins results in a further decrease in stroke or other cardiovascular event, but now things have changed and future directions include combinations with ezetimibe and new treatments such as PCSK9 inhibitors. Only time will tell the real roll of these new promising non-statin lipid-modifying therapies on stroke prevention. PMID: 27160755 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - May 9, 2016 Category: Drugs & Pharmacology Authors: Castilla-Guerra L, Del Carmen Fernandez-Moreno M, Colmenero-Camacho MA Tags: Curr Pharm Des Source Type: research

Statins in Stroke Prevention: Present and Future.
CONCLUSION: Traditionally, there has been no clear data demonstrating that adding other lipid-modifying drugs to statins results in a further decrease in stroke or other cardiovascular event, but now things have changed and future directions include combinations with ezetimibe and new treatments such as PCSK9 inhibitors. Only time will tell the real roll of these new promising non-statin lipidmodifying therapies on stroke prevention. PMID: 27160755 [PubMed - in process]
Source: Current Pharmaceutical Design - October 30, 2016 Category: Drugs & Pharmacology Authors: Castilla-Guerra L, Del Carmen Fernandez-Moreno M, Colmenero-Camacho MA Tags: Curr Pharm Des Source Type: research

Genetic Signatures in the Treatment of Stroke.
Abstract Stroke is the fourth leading cause of mortality and neurological disability. It is caused by an intricate interplay of environmental and genetic factors. Genes not only influence susceptibility to stroke but have also been found to alter the response to pharmacological agents and may also influence the clinical outcome of the disease. Current treatment strategies for stroke include tissue plasminogen activator, antiplatelet agents and lipid lowering drugs. These act via diverse mechanisms of actions and are centered around the management of modifiable risk factors to prevent the recurrent stroke events. H...
Source: Current Pharmaceutical Design - August 26, 2014 Category: Drugs & Pharmacology Authors: Munshia A, Sharma V Tags: Curr Pharm Des Source Type: research

Brain Drug Delivery Systems for the Stroke Intervention and Recovery.
CONCLUSION: Combined with new drug targets in the treatment of stroke, BDDS will provide more effective therapeutics for stroke intervention and recovery. PMID: 27784243 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - October 24, 2016 Category: Drugs & Pharmacology Authors: Luo T, Wang J, Hao S, Guo T, Ren P, Cheng Z, Gao F, Gong Y, Wang B Tags: Curr Pharm Des Source Type: research

Oral antiplatelet and anticoagulant agents in the prevention and management of ischemic stroke.
Abstract Despite numerous advances over the last 50 years, stroke continues to be a leading cause of death and disability worldwide. The treatment and prevention of stroke has undergone extensive study, and significant advances in medical management have occurred within the past decade principally with the development of new classes of orally active anticoagulant drugs. Here we review these recent breakthroughs and the varying roles of anticoagulants and antiplatelet agents in the prevention and management of different ischemic stroke subtypes, as well as describe the benefits and ongoing challenges to incorporati...
Source: Current Pharmaceutical Design - December 20, 2016 Category: Drugs & Pharmacology Authors: Shrestha S, Coy S, Bekelis K Tags: Curr Pharm Des Source Type: research

The Role of Blood-Brain Barrier Transporters in Pathophysiology and Pharmacotherapy of Stroke.
Abstract Cerebral ischemia is one of the major causes of disability worldwide. In cerebral ischemic stroke, occlusion of a major cerebral artery by an embolus or local thrombosis can result in transient or permanent reduction of cerebral blood flow to a portion of the brain, resulting in deprivation of glucose and oxygen. Since the brain relies on a continuous supply of nutrients and ions via mostly carrier mediated processes across the blood-brain barrier (BBB), any irregularity in these transport mechanisms dramatically affects neuronal function and outcome after acute and chronic stroke. Despite numerous encour...
Source: Current Pharmaceutical Design - June 19, 2013 Category: Drugs & Pharmacology Authors: Shah K, Abbruscato T Tags: Curr Pharm Des Source Type: research

Clinical Effects of Dual Antiplatelet Therapy or Aspirin Monotherapy after Acute Minor Ischemic Stroke or Transient Ischemic Attack, a Meta-Analysis
CONCLUSIONS: Among patients with acute minor ischemic stroke or TIA, DAPT, as compared with aspirin monotherapy, might offer better effectiveness in terms of ischemic stroke recurrence at the expense of a higher risk of major bleeding. The trade-off between ischemic benefits and bleeding risks should be assessed in tailoring the therapeutic strategies.PMID:34323179 | DOI:10.2174/1381612827666210728102459
Source: Current Pharmaceutical Design - July 29, 2021 Category: Drugs & Pharmacology Authors: Francesco Condello Gaetano Liccardo Giuseppe Ferrante Source Type: research

Antiplatelet treatment in stroke: new insights.
CONCLUSIONS: Treatment with an antiplatelet agent is recommended to reduce recurrent stroke and death in patients with a non-cardioembolic ischemic stroke or transient ischemic attack. Moreover, clinicians should carefully assess the pros and cons in each case and individualize the need for prolonged dual antiplatelet therapy. PMID: 27291399 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - June 8, 2016 Category: Drugs & Pharmacology Authors: Milionis H, Liontos A, Vemmos K, Spengos K Tags: Curr Pharm Des Source Type: research

Long Noncoding RNAs as Diagnostic and Therapeutic Targets for Ischemic Stroke.
Abstract LncRNAs (long non-coding RNAs) are endogenous molecules lacking protein-encoding capacity, which have been identified as key regulators of ischemic stroke. Increasing evidence suggests that lncRNAs play critical roles in several aspects of ischemic stroke, including atherosclerosis, dyslipidemia, hypertension, and diabetes mellitus. Hence, lncRNAs may further broaden our understanding of stroke pathogenesis. Altered lncRNA expression has been found in rodent focal cerebral ischemia models and oxygen-glucose deprived mouse brain microvascular endothelial cells as well as stroke patients. LncRNAs are consid...
Source: Current Pharmaceutical Design - March 26, 2019 Category: Drugs & Pharmacology Authors: Wang Q, Liu X, Zhu R Tags: Curr Pharm Des Source Type: research

LncRNAs a new target for post-stroke recovery.
Abstract LncRNAs (long non-coding RNAs) are endogenous molecules and involved in complicated biological processes. Increasing evidence has shown that lncRNAs play a vital role in the post-stroke pathophysiology.Furthermore, several lncRNAs were reported to mediate ischemia cascade processes include apoptosis, excitotoxicity, oxidative stress, angiogensis, neuroinfla- mmation, microglial cell which can cause neuron injury and influence neuron recovery after ischemic stroke. In our study, we first summarize current development about lncRNAs and post-stroke, focus on the regulatory roles of lncRNAs on pathophysiology...
Source: Current Pharmaceutical Design - February 24, 2020 Category: Drugs & Pharmacology Authors: Zhao J, Jun Y, Liu X, Zhu R Tags: Curr Pharm Des Source Type: research